| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
EVP Research &Preclinical Dev
1 company
Liau Gene is an EVP Research &Preclinical Dev at Stoke Therapeutics, Inc.. Recent SEC Form 4 filings include 0 buys and 11 sells.
Estimated insider holdings value: $842K based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Mar 2, 2021 | STOK Stoke Therapeutics, Inc. | EVP Research &Preclinical Dev | Sale+OE | 5,344 | $62.93 | $336,297.16 | -7.4% | |
| Oct 19, 2020 | STOK Stoke Therapeutics, Inc. | EVP Research &Preclinical Dev | Sale+OE | 37,851 | $38.16 | $1,444,205.77 | -44.2% | |
| Oct 13, 2020 | STOK Stoke Therapeutics, Inc. | EVP Research &Preclinical Dev | Sale+OE | 1,649 | $40.00 | $65,960.00 | -10.9% | |
| Jun 1, 2020 | STOK Stoke Therapeutics, Inc. | EVP Research &Preclinical Dev | Sale+OE | 20,000 | $26.35 | $527,036.83 | -28.2% | |
| May 22, 2020 | STOK Stoke Therapeutics, Inc. | EVP Research &Preclinical Dev | Sale+OE | 7,500 | $30.00 | $225,000.00 | -35.7% |